Sequence
39 amino acids
Origin
Synthetic triple incretin agonist
Research Dose
Phase 2 protocols used doses ranging from 0.5mg to 12mg weekly subcutaneous. Optimal dose appears to be 8-12mg/week based on efficacy/tolerability balance.
Category
Weight Loss
How It Works
Retatrutide is a first-in-class triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor activation enhances energy expenditure and fat oxidation beyond what dual agonists achieve. Phase 2 trials showed unprecedented weight loss of up to 24% body weight.
Key Benefits
Triple GIP/GLP-1/glucagon receptor agonist
Highest weight loss in clinical trials to date
May improve metabolic health comprehensively
Novel mechanism of action
Research Highlights
Phase 2 trial showed 24.2% weight loss at highest dose (48 weeks)
Triple agonist: GIP + GLP-1 + glucagon receptors
Greater weight loss than both semaglutide and tirzepatide in early data
Phase 3 trials ongoing (TRIUMPH program)
May benefit liver fat reduction (MASLD/NASH)
Available Forms
- Subcutaneous injection
- Lyophilized powder (research)
Legal Status
Retatrutide is an investigational drug in Phase 3 clinical trials by Eli Lilly. Not yet approved in any country. Research-grade available from peptide suppliers.
Research & Education Only — The information on this page is for research and educational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before making any decisions.